DekaBank Deutsche Girozentrale
SGMO

DekaBank Deutsche Girozentrale’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-76,900
Closed -$127K – 1315
2023
Q1 		$127K Hold
76,900
– – ﹤0.01% 1232
2022
Q4 		$226K Hold
76,900
– – ﹤0.01% 1204
2022
Q3 		$369K Hold
76,900
– – ﹤0.01% 1101
2022
Q2 		$306K Hold
76,900
– – ﹤0.01% 1118
2022
Q1 		$456K Buy
76,900
+7,000
+10% +$41.6K ﹤0.01% 1076
2021
Q4 		$548K Buy
69,900
+2,000
+3% +$17.4K ﹤0.01% 1078
2021
Q3 		$618K Hold
67,900
– – ﹤0.01% 1004
2021
Q2 		$786K Hold
67,900
– – ﹤0.01% 966
2021
Q1 		$786K Hold
67,900
– – ﹤0.01% 952
2020
Q4 		$1.19M Sell
67,900
-3,400
-5% -$39.8K ﹤0.01% 815
2020
Q3 		$695K Buy
+71,300
New +$771K ﹤0.01% 857
2019
Q4 		– Sell
-73,700
Closed -$677K – 1212
2019
Q3 		$677K Sell
73,700
-78,700
-52% -$883K ﹤0.01% 730
2019
Q2 		$1.61M Buy
152,400
+95,700
+169% +$1.02M 0.01% 682
2019
Q1 		$1.03M Buy
56,700
+10,500
+23% +$107K 0.01% 755
2018
Q4 		$489K Sell
46,200
-10,500
-19% -$130K ﹤0.01% 836
2018
Q3 		$1.03M Sell
56,700
-1,500
-3% -$22.8K 0.01% 769
2018
Q2 		$809K Buy
58,200
+20,000
+52% +$332K 0.01% 798
2018
Q1 		$753K Buy
+38,200
New +$817K 0.01% 788
2016
Q2 		– Sell
-36,500
Closed -$210K – 1037
2016
Q1 		$210K Buy
36,500
+800
+2% +$4.8K ﹤0.01% 843
2015
Q4 		$336K Buy
35,700
+500
+1% +$3.85K ﹤0.01% 773
2015
Q3 		$199K Buy
35,200
+1,500
+4% +$12.4K ﹤0.01% 871
2015
Q2 		$374K Buy
33,700
+1,300
+4% +$16.8K ﹤0.01% 762
2015
Q1 		$508K Sell
32,400
-4,100
-11% -$63.4K 0.01% 709
2014
Q4 		$541K Sell
36,500
-3,500
-9% -$42.5K 0.01% 674
2014
Q3 		$431K Buy
40,000
+1,000
+3% +$13.1K 0.01% 688
2014
Q2 		$596K Buy
39,000
+1,900
+5% +$27.3K 0.01% 576
2014
Q1 		$671K Buy
37,100
+2,800
+8% +$54K 0.01% 532
2013
Q4 		$483K Buy
34,300
+4,500
+15% +$51.8K 0.01% 552
2013
Q3 		$313K Buy
+29,800
New +$296K 0.01% 596

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DekaBank Deutsche Girozentrale's SGMO Position: Q2 2023 in Review

DekaBank Deutsche Girozentrale sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2023, closing a stake of 76,900 shares — an estimated $127K sold.

DekaBank Deutsche Girozentrale first reported a position in SGMO in Q3 2013 and held it in 29 quarters. The position peaked at $1.61M in Q2 2019. 152 funds tracked by Wall St. Rank hold SGMO as of Q2 2023.

  • DekaBank Deutsche Girozentrale reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2023 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 76,900 SANGAMO THERAPEUTICS INC shares in Q2 2023, an estimated $127K.
  • DekaBank Deutsche Girozentrale first reported a position in SANGAMO THERAPEUTICS INC in Q3 2013 and held it in 29 quarters.
  • DekaBank Deutsche Girozentrale's SANGAMO THERAPEUTICS INC position peaked at $1.61M in Q2 2019.
  • 152 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2023.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2023, filed 25 Jul 2023.